What is PT-141?
PT-141 (Bremelanotide) is a synthetic peptide analog of alpha-Melanocyte Stimulating Hormone (α-MSH). Originally developed as a sunless tanning agent (Melanotan II), researchers discovered that its active metabolite, PT-141, had powerful aphrodisiac and arousal-stimulating effects. Unlike traditional erectile dysfunction drugs (like sildenafil) that target the vascular system, PT-141 acts directly on the nervous system to stimulate arousal.
How does PT-141 work?
PT-141 is a non-selective agonist of melanocortin receptors, primarily targeting MC3 and MC4 receptors in the central nervous system. Activation of these receptors in the brain's hypothalamus triggers downstream neural pathways associated with sexual motivation, desire, and erectile function. Because it bypasses the vascular system, it is effective in cases where vascular drugs fail.
Primary Documented Uses
- Treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women (Vyleesi)
- Alternative treatment for male Erectile Dysfunction (ED), particularly psychogenic ED
- Increasing libido and sexual motivation
Research Summary
Bremelanotide has been extensively evaluated in large-scale human clinical trials. It demonstrated statistically significant efficacy in increasing sexual desire and reducing distress associated with Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. In men, it successfully induced erections. The most common side effects reported are transient nausea, flushing, and temporary blood pressure elevation.
Legal and Regulatory Status
Bremelanotide (as the brand name Vyleesi) is FDA-approved for the treatment of generalized HSDD in premenopausal women. It is a prescription-only medication. Custom compounded versions are available from qualified compounding pharmacies, though strict regulatory oversight applies.
Frequently Asked Questions
What is PT-141?
PT-141 is An FDA-approved peptide that targets the central nervous system to treat sexual arousal disorders in both men and women.
How does PT-141 work?
PT-141 is a non-selective agonist of melanocortin receptors, primarily targeting MC3 and MC4 receptors in the central nervous system. Activation of these receptors in the brain's hypothalamus triggers downstream neural pathways associated with sexual motivation, desire, and erectile function. Because it bypasses the vascular system, it is effective in cases where vascular drugs fail.
What does research say about PT-141?
Bremelanotide has been extensively evaluated in large-scale human clinical trials. It demonstrated statistically significant efficacy in increasing sexual desire and reducing distress associated with Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. In men, it successfully induced erections. The most common side effects reported are transient nausea, flushing, and temporary blood pressure elevation.
Is PT-141 FDA-approved or legally available?
Bremelanotide (as the brand name Vyleesi) is FDA-approved for the treatment of generalized HSDD in premenopausal women. It is a prescription-only medication. Custom compounded versions are available from qualified compounding pharmacies, though strict regulatory oversight applies.